Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections

Who May Qualify: - Hospitalized male or female≥18 and ≤80 years of age， - Participant must have a diagnosis of an infection (HABP/VABP, cUTI, cIAI, BSI) due to confirmed Carbapenem-Resistant Enterobacteriaceae infection, requiring administration of IV antibacterial therapy - Participant who had received appropriate prior empiric antibacterial therapy for a carbapenem-resistant pathogen must meet at least 1 of the following criteria: no or no more than 24h; worsening of objective symptoms or signs after at least 48 hours of antibacterial therapy; no change of objective symptoms or signs after at least 72 hours of antibacterial therapy - The estimated survival time is more than 28 days - Understand and abide by the research procedures and methods, voluntarily participate in this research, and sign an willing to sign a consent form form Who Should NOT Join This Trial: - Participants who need more than 3 systemic antibiotics as part of best available treatment (BAT) - Participant is expected to require more than 21 days of treatment - Acute Physiology and Chronic Health Evaluation (APACHE) II score \>30 using the most recent available data - Other medical or psychiatric condition may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study. - Those who participated in other clinical trials within 28 days before randomization and used any test drugs or medical devices Always talk to your doctor about whether this trial is right for you.